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Abstract
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INTRODUCTION—There is limited understanding of relationships between genotype, phenotype
and other conditions contributing to health in neonates with medium-chain acyl-coenzyme A
dehydrogenase deficiency (MCADD) identified through newborn screening.
METHODS—Retrospective analysis of comprehensive data from a cohort of 221 newbornscreened subjects identified as affected with MCADD in the Inborn Errors of Metabolism –
Information System (IBEM-IS), a long term follow-up database of the Inborn Errors of
Metabolism Collaborative, was performed.

Author Manuscript

c
Corresponding author: Susan A. Berry, M.D., Professor and Director, Division of Genetics and Metabolism, Departments of
Pediatrics and Genetics, Cell Biology & Development, University of Minnesota, berry002@umn.edu, fax 612-626-2993, Phone
612-624-7144; Mailing Address: University of Minnesota, Department of Pediatrics, 420 Delaware St SE MMC 75, Minneapolis MN
55455; Express Address: University of Minnesota, Department of Pediatrics, 515 Delaware St SE, 4-150MT, Minneapolis MN 55455.
*For the Inborn Errors of Metabolism Collaborative: University of Colorado School of Medicine and Children’s Hospital Colorado
(Janet Thomas, Melinda Dodge); Emory University Department of Human Genetics (Rani Singh, Sangeetha Lakshman, Katie
Coakley, Adrya Stembridge); University of Iowa Health Care (Alvaro Serrano Russi, Emily Phillips); Ann and Robert H. Lurie
Children’s Hospital of Chicago (Barbara Burton, Clare Edano, Sheela Shrestha); University of Illinois (George Hoganson, Lauren
Dwyer); Indiana University (Bryan Hainline, Susan Romie, Sarah Hainline); University of Louisville (Alexander Asamoah, Kara
Goodin, Cecilia Rajakaruna, Kelly Jackson); Johns Hopkins (Ada Hamosh, Hilary Vernon, Nancy Smith); University of Michigan
(Ayesha Ahmad, Sue Lipinski); Wayne State University Children’s Hospital of Michigan (Gerald Feldman); University of Minnesota
(Susan Berry, Sara Elsbecker); Minnesota Department of Health (Kristi Bentler); University of Missouri (Esperanza FontMontgomery, Dawn Peck); Duke University (Loren D.M. Pena, Dwight D. Koeberl, Yong-hui, Jiang, Priya S. Kishnani); University of
Nebraska (William Rizzo, Machelle Dawson, Nancy Ambrose); Children’s Hospital at Montefiore (Paul Levy); New York Medical
College (David Kronn); University of Rochester (Chin-to Fong, Kristin D’Aco, Theresa Hart); Women’ and Children’s Hospital of
Buffalo (Richard Erbe, Melissa Samons); Cincinnati Children’s Hospital Medical Center (Nancy Leslie, Racheal Powers); Nationwide
Children’s Hospital (Dennis Bartholomew, Melanie Goff); Oregon Health and Science University (Sandy vanCalcar, Joyanna Hansen);
University of Pittsburgh School of Medicine (Georgianne Arnold, Jerry Vockley); Children’s Hospital of Pittsburgh of UPMC (Cate
Walsh-Vockley); Medical College of Wisconsin (William Rhead, David Dimmock, Paula Engelking, Cassie Bird, Ashley Swan);
University of Wisconsin (Jessica Scott Schwoerer, Sonja Henry); West Virginia University (TaraChandra Narumanchi, Marybeth
Hummel, Jennie Wilkins); Sanford Children’s Specialty Clinic (Laura Davis-Keppen, Quinn Stein, Rebecca Loman); Michigan Public
Health Institute (Cynthia Cameron, Mathew J. Edick, Sally J. Hiner, Kaitlin Justice, Shaohui Zhai).

Bentler et al.

Page 2

Author Manuscript

RESULTS—The average age at notification of first newborn screen results to primary care or
metabolic providers was 7.45 days. The average octanoylcarnitine (C8) value on first newborn
screen was 11.2 umol/L (median 8.6, range 0.36–43.91). A higher C8 level correlated with an
earlier first subspecialty visit. Subjects with low birth weight had significantly lower C8 values.
Significantly higher C8 values were found in symptomatic newborns, in newborns with abnormal
lab testing in addition to newborn screening and/or diagnostic tests, and in subjects homozygous
for the c.985A>G ACADM gene mutation or compound heterozygous for the c.985A>G mutation
and deletions or other known highly deleterious mutations. Subjects with neonatal symptoms, or
neonatal abnormal labs, or neonatal triggers were more likely to have at least one copy of the
severe c.985A>G ACADM gene mutation. C8 and genotype category were significant predictors
of the likelihood of having neonatal symptoms. Neonates with select triggers were more likely to
have symptoms and laboratory abnormalities.
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CONCLUSIONS—This collaborative study is the first in the United States to describe health
associations of a large cohort of newborn-screened neonates identified as affected with MCADD.
The IBEM-IS has utility as a platform to better understand the characteristics of individuals with
newborn-screened conditions and their follow-up interactions with the health system.
Keywords
medium-chain acyl-coenzyme A dehydrogenase deficiency; MCAD; octanoylcarnitine; ACADM;
newborn screening; inborn error of metabolism

1. INTRODUCTION
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Medium-chain acyl-coenzyme A dehydrogenase deficiency (MCADD) is an autosomal
recessive mitochondrial fatty acid oxidation disorder. A recent report on the birth prevalence
of disorders detectable through newborn bloodspot screening noted an overall MCADD birth
prevalence of 5.3 (4.1–6.7, 99% CI) per 100,000 births across a variety of racial/ethnic
groups (1). Impaired hepatic ketogenesis resulting in hypoketotic hypoglycemia, metabolic
acidosis, liver disease, and lethargy can rapidly progress to coma and death when glycogen
stores are depleted during catabolic physiological states (2). Undiagnosed, morbidity and
mortality are considerable, but when the diagnosis is known, MCADD can be successfully
managed and outcomes improved (3). Early detection of affected infants is important (4).
Thus, MCADD is a core condition on the U.S. Department of Health and Human Services
Advisory Committee on Heritable Disorders in Newborns and Children’s Recommended
Uniform Screening Panel and newborn screening for this condition is done in all 50 U.S.
states, the District of Colombia and Puerto Rico (5) (6). Despite an acknowledgement that
this condition can have a significant health impact in early life, limited understanding exists
of the complex interplay between genotype, biochemical phenotype, and other conditions
associated with health outcomes of neonates with MCADD.
Accumulation of the medium-chain acylcarnitine species is characteristic of MCADD, with
octanoylcarnitine (C8) as the prominent blood marker (7). Higher C8 values in blood spot
newborn screening have been reported in association with homozygosity for the common c.
985A>G pathogenic gene variant (8), or the presence of other severe pathogenic variants
such as deletion, nonsense, or splice site mutations in the ACADM gene (9). Higher blood
Mol Genet Metab. Author manuscript; available in PMC 2017 September 01.
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spot C8 values have also been reported in MCADD affected neonates, particularly those
homozygous for the c.985A>G mutation, whose blood spots were collected sooner after
birth (10).
This is the first multi-state, multi-center collaborative study in the United States to describe
associations between newborn screen C8 values, ACADM genotype, clinical circumstances
and symptoms, and clinical laboratory abnormalities in a large cohort of newborn-screened
neonates identified as affected with MCADD.

Author Manuscript

Using data submitted by the Inborn Errors of Metabolism Collaborative, this study sought to
learn if first newborn screen C8 values are related to gender, genotype, birth weight, or
initial food source. We investigated whether C8 values are associated with the presence of
neonatal triggers, the presence of neonatal symptoms, and the presence of neonatal abnormal
lab results in addition to newborn screening or diagnostic tests. We also assessed if the
presence of neonatal triggers is associated with the manifestation of neonatal symptoms and
abnormal neonatal labs. We examined if there are correlations between first newborn screen
C8 value and birth weight, and days of age at the first subspecialist visit, and if potential
correlations between C8 value and the days of age at the first subspecialist visit differ
between subjects with and without neonatal triggers, with and without neonatal symptoms,
with and without neonatal abnormal labs. Finally, we sought associations between ACADM
genotype and neonatal triggers, neonatal symptoms, and neonatal abnormal labs and
examined if C8 values and genotype category predict whether a subject manifests neonatal
symptoms.

2. METHODS
Author Manuscript

2.1. DATA
The research protocol was approved by the Institutional Review Boards of the Inborn Errors
of Metabolism Collaborative (IBEMC) partners and informed consent was documented in
the Inborn Errors of Metabolism – Information System (IBEM-IS) for all enrolled MCADD
subjects (11) (12). The IBEMC data collection began in 2007 and is currently managed
using REDCap electronic data capture tools hosted at the Michigan Public Health Institute
(MPHI) (13).

Author Manuscript

Data for this study were extracted from the IBEM-IS on August 7, 2015. The inclusion
criteria for this study were subjects having: 1) consented for data-sharing, 2) assignment of
the condition MCADD, 3) abnormal newborn screening result, and 4) a first newborn screen
C8 value. Newborn screen MCADD-related acylcarnitine values other than C8 were not
included in this study due to insufficient data collection on those values in the IBEM-IS.
Blood spot collection timing was unavailable for most subjects.
2.2. VARIABLES
The IBEM-IS defines the neonatal period as the first 28 days of life. It does not require
specification of whether recorded neonatal complications, symptoms and abnormal labs are
clinically determined to be caused by or related to MCADD. For this analysis, we
reclassified the documented neonatal complications, symptoms and abnormal labs into three
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types: 1) neonatal triggers, 2) neonatal symptoms, and 3) neonatal abnormal labs, and
defined “neonatal” as those that were known to have occurred within the first 28 days of life.
Neonatal triggers were defined as neonatal complications and interventions suggestive of
underlying health complications determined by clinician authors as most likely to result in
potential MCADD symptoms. Neonatal symptoms were defined by clinician authors as
symptoms consistent with MCADD, many based on reports of symptoms manifested in
individuals affected with MCADD (9) (14) (15) (16) (17) (18) (19) (20). Neonatal abnormal
labs were defined by clinician authors as laboratory test abnormalities of potential concern
in the context of MCADD (excluding newborn screening and MCADD diagnostic
biochemical and molecular test results). The IBEM-IS data did not allow for determination
of whether jaundice and hyperbilirubinemia during the neonatal period reflected physiologic
versus pathogenic newborn conditions. To avoid possible over-estimation of the neonatal
symptoms/abnormal labs classified as associated with MCADD, we excluded jaundice/
hyperbilirubinemia from the analyses. Birth weight was treated both as a continuous variable
and was also categorized as low birth weight (<=2.5 kg), or not. The source of neonatal
nutrition was categorized as breastfed only, or not. Age at first visit, age at notification, and
age at intervention are age of days since birth until the subject was first seen by a
subspecialist, the subject’s primary care or metabolic provider was first notified of the
newborn screening results, and the intervention for MCADD was initiated, respectively. C8
is the octanoylcarnitine value, measured in umol/L, on the first newborn screen.
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To analyze genotype, alleles were categorized based on documented ACADM gene allele
findings (Table 5). The categories were as follows: A) the c.985A>G mutation (21) (22), B)
ACADM deletions, and mutations other than c.985A>G for which reports of decreased fatty
acid oxidation in fibroblast studies or considerably decreased MCAD enzyme activity were
found in published literature (23) (24) (25) (26) (27) (28) (29), C) all other allele findings
not meeting criteria for A or B (4) (23) (25) (29) (30) (31) (32) (33) (34) (35), and D) empty
or indecipherable entries in the allele data fields, as data are entered as free text. The dataset
contained eight combinations of two alleles: AA (n=69), AB (n=18), BB (n=1), AC (n=49),
AD (n=26), CC (n=12), CD (n=2), and DD (n=44). The BB group contained too few cases
to compute stable statistics and was excluded from genotype analysis. The AD, CD, and DD
groups were also excluded from analysis due to the lack of usable genotype information.
The remaining four genotype categories were further collapsed into two categories for
selected additional analyses as follows: 1) AA and AB, and 2) AC and CC.
2.3 STATISTICAL ANALYSES
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The Mann-Whitney U test was used to assess differences in C8 values between each pair of
groups, defined by: low birth weight or not, breastfed only or not, presence or absence of
neonatal triggers, presence or absence of neonatal symptoms, presence or absence of
neonatal abnormal labs, and the two collapsed genotype categories. The Kruskal-Wallis test
was used to compare C8 values among the four genotype categories. Correlations between
C8, birth weight and age at first visit were tested using the Spearman correlation test. Chisquare tests were used to test the associations between categorical variables.
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To further examine whether the strength of the relationship between C8 and age at first visit
differs between each pair of subgroups defined by, presence or absence of neonatal triggers,
presence or absence of neonatal symptoms, and presence or absence of neonatal abnormal
labs, we constructed three generalized linear models (negative binomial with log link
function). In each model, age at first visit was the dependent variable, C8 and one of the
above three binary variables, along with the interaction term, were the independent
variables.
Logistic regression with neonatal symptoms as the binary outcome variable, and the
collapsed genotype category, C8, and gender as predictors, was conducted to determine
whether these variables predict the likelihood of developing neonatal symptoms.
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All statistical significance tests were two-sided. Bonferroni correction was used to adjust for
multiple comparisons to keep the overall significance level at α=0.05. All the statistical
analyses were conducted in IBM SPSS Statistics for Windows, Version 23.0.

3. RESULTS
A total of 337 consented subjects were assigned the condition MCADD, 285 (85%) of
whom had abnormal newborn screening. Of the 285 subjects, 223 had a first newborn screen
C8 value documented in the IBEM-IS. Two subjects with first newborn screen C8 values
presumed to be erroneously recorded (2406 umol/L and 1738 umol/L) were excluded. The
remaining 221 subjects, all identified in the IBEM-IS as alive at the time of data extraction,
constituted the dataset for this study.
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Age of subjects at IBEMC enrollment ranged from infancy to 10 years (n=218). Average
reported birth weight was 3.35 kg (n=213, Std. Dev.=0.53). Subjects’ first newborn screen
C8 value averaged 11.2 umol/L (median=8.6, range 0.36–43.91, Std. Dev.=10.12). MCADD
diagnostic testing was documented to be done for the majority of subjects in this cohort
(Table 1).
Eligibility for enrollment in the IBEMC is dependent upon the individual having been given
a diagnosis of an inborn error of metabolism, in this case, MCADD. Diagnostic methods and
results were documented in the IBEM-IS for the majority of subjects with MCADD included
in this study (Table 2).

Author Manuscript

The majority of subjects had at least one clinical biochemical diagnostic laboratory test
abnormality and/or two ACADM allele findings recorded in the IBEM-IS (N=189, 86%).
Among the five subjects with normal biochemical diagnostic testing recorded, three had two
ACADM allele findings, with genotype categories AA, CC, and CC. The two CC subjects
had normal plasma acylcarnitine profiles, the AA subject had normal urine organic acids,
and additional biochemical diagnostic testing results were not recorded for these three
subjects. The remaining two subjects had one allele finding, both with normal urine organic
acids and without other biochemical diagnostic testing results recorded.
Subjects’ average age at notification of the first abnormal newborn screen to a primary care
or metabolic provider was 7.45 days (n=191, Std. Dev.=19.44). Average age since birth to
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initiation of intervention for MCADD was 8.11 days (n=197, Std. Dev.=19.41). Subjects
averaged 16.77 days of age at the time of the first subspecialist visit (n=202, Std.
Dev.=22.27).
The types and frequencies of select neonatal clinical characteristics and laboratory
abnormalities in our dataset are summarized in Table 3.

Author Manuscript

C8 values and age at first visit were negatively correlated (p = 0.001, Spearman’s rho =
−0.227) indicating subjects seen by subspecialists sooner had higher C8 levels. Generalized
linear regression results confirmed the negative correlation; for every one unit increase in
C8, age at first visit decreased by 2% (p < 0.001). While the correlation was stronger (more
negative) in subjects who had neonatal symptoms or neonatal abnormal labs than for
subjects who did not, the difference in the magnitude of the correlation was not statistically
significant.
There was no difference in C8 values between males and females (mean rank=112 vs. 110,
p=0.76), nor between breastfed-only subjects and those whose neonatal diet contained other
types of nutrition such as formula, total parenteral nutrition, and/or intralipids, plus or minus
breast milk (mean rank=90 vs. 84, p=0.43). Subjects with birth weight less than or equal to
2.5 kg had significantly lower C8 values than the rest (mean rank=73 vs. 109, p=0.04).
Significantly higher C8 values were found in subjects with neonatal symptoms (mean
rank=114 vs. 86, p=0.008), and in subjects with neonatal abnormal labs (mean rank=59 vs.
41, p=0.003). There was no significant difference in C8 values between subjects with and
without neonatal triggers (mean rank=107 vs. 98, p=0.388) (Table 4), although subjects with
neonatal triggers were more likely to have neonatal symptoms and neonatal abnormal labs
(p<0.001 in both tests, results not shown).
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C8 values significantly differed among the four genotype categories (p<0.001). Post hoc
pairwise comparisons showed C8 values significantly higher in the AA genotype group than
in the AC (adjusted p<0.001) and CC (adjusted p=0.001) groups; and C8 values significantly
higher in the AB genotype group than in the AC group (adjusted p=0.046). Although the
data suggested a difference in C8 values between the AB genotype and the CC genotype
groups, the test failed to reach statistical significance (adjusted p=0.144), which may be due
to low power. C8 values were significantly higher in the AA&AB group than in the AC&CC
group (p<0.001). Figure 1 shows the mean, median, and rank of C8 value for the fourcategory and two-category genotype variables.
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For subjects with recorded and decipherable ACADM allele findings in the IBEM-IS, the c.
985A>G mutation was most frequently appearing. The c.199T>C allele was the next most
frequently appearing, with twelve subjects compound heterozygous for this allele and the c.
985A>G mutation, and two subjects heterozygous for this allele and two other C type
alleles. Subjects with the c.985A>G/c.199T>C genotype had first newborn screen C8 values
ranging from 1.28–5.43 umol/L) and either no or unknown triggers, symptoms or abnormal
labs in the first 28 days of life. The other two subjects with the c.199T>C/other C type
genotype had first newborn screen C8 values of ≤0.6 umol/L, and had no triggers, symptoms
or abnormal labs in the first 28 days of life.
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Additionally, the proportions of subjects with genotype category AA or AB were
significantly higher in subjects who had neonatal symptoms, neonatal abnormal labs, or
neonatal triggers than the proportions in subjects recorded as asymptomatic (91% vs 52%,
p=0.001, Phi=0.298)., without abnormal labs (88% vs 58%, p=0.032, Phi=0.275),, or
without triggers during neonatal period (81% vs 55%, p=0.009, Phi=0.227). Further analysis
demonstrated that both the two-category genotype variable and C8 were significant
predictors of the likelihood of having neonatal symptoms. For every one unit increase in C8
value, the odds of having neonatal symptoms increased by 6% (p=0.016, EXP(B)=1.06).
The odds of having neonatal symptoms in subjects with AA or AB genotype was 4.93 times
of that in subjects with AC, or CC (p=0.050, EXP(B)=4.93).

4. CONCLUSIONS
Author Manuscript

This collaborative study is the first in the United States to describe health associations of a
large cohort of newborn-screened neonates with MCADD. The IBEM-IS platform was
designed to allow examination of complex associations between newborn screening results,
clinical conditions and laboratory findings of individuals with inborn errors of metabolism.
The IBEM-IS data increases our understanding of interactions with public health and
clinical systems related to the notification and follow-up of abnormal newborn screening
results for children with rare inborn errors of metabolism. The opportunity to examine a
large cohort of newborn screened individuals with MCADD expands understanding of
factors associated with their health in the first 28 days of life.
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In 2014, the Society of Inherited Metabolic Disorders identified MCADD as one of several
critical conditions requiring immediate notification of the health care provider upon
ascertainment of an abnormal newborn screening result (36). Recently, the Advisory
Committee on Heritable Disorders in Newborns and Children recommended that
presumptive positive screening results for time-critical conditions be immediately reported
to the child’s health care provider and by no later than 5 days of life (37). Our subjects had a
longer documented mean age (7.45 days) at the time of newborn screen result notification
indicating that improvement in timely notification must remain a priority to minimize risks
of symptom initiation in these vulnerable newborns. Initiation of MCADD intervention
occurred at a mean age of 8 days in our cohort. The close proximity in time of notification
and intervention reflects the priority of clinicians to intervene in the care of newborns with
possible MCADD as soon as possible.
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In an attempt to determine if poor initiation of breast-feeding might be a risk factor for
neonates with this condition, we specifically queried whether the diet of the neonates was
associated with C8 values. Despite the failure to observe an association between high C8
values and exclusive breast-feeding in this data analysis, neonates who are exclusively
breast-fed and in whom initiation of feeding is problematic may well be at additional risk for
decompensation. Our observations cannot rule out poor breastfeeding initiation as a risk
factor without additional information about this specific issue.
C8 values >0.3 umol/L along with additional results of MCADD-related ratios have been
considered by some as indicative of MCADD by neonatal screening (20) (38). A worldwide

Mol Genet Metab. Author manuscript; available in PMC 2017 September 01.

Bentler et al.

Page 8

Author Manuscript

collaborative project looking at the clinical validation of the cutoff target range of C8 in
tandem mass spectrometry newborn screening describes disorder ranges for acylcarnitines
and related ratios in MCADD, creating a tool for assessing screening results (39). Although
all subjects in our cohort had a first newborn screen C8 value ≥0.36 umol/L, data available
did not uniformly include additional newborn screening acylcarnitine values or ratios,
preventing inclusion in our data analysis. The significant associations we found between the
first newborn screen C8 value and low birth weight, symptoms, and clinical lab
abnormalities for neonates with MCADD highlight the importance of providing quantitative
screening result data to clinicians caring for children with abnormal newborn screen results
for MCADD. Clinicians receiving such results should view very high C8 values as a signal
for increased concern for symptomatic presentation of the condition.
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Overrepresentation of infants with flagged newborn screening acylcarnitine values among
infants in neonatal intensive care or with very low birth weight has been reported (10).
Distribution of blood spot C8 concentrations did not vary greatly by birth weight in another
study (40). In our study, neonates with MCADD in the low birth weight (<=2.5 kg) group
had significantly lower C8 values. Although some of our low birth weight subjects had
neonatal triggers, most had neither neonatal symptoms nor neonatal abnormal labs, and 7 out
of 13 were homozygous for the c.985A>G ACADM mutation. These findings suggest that
low birth weight itself may be a factor associated with lower newborn screen C8 values than
might otherwise be expected given risk factors such as a deleterious genotype. The relative
lower C8 values in this group may be due to these babies with low birth weight already
receiving medical care with adequate prevention of fasting to prevent MCADD-associated
complications causing elevations of C8. Data collection regarding the timing of first
newborn screen sampling was a relatively recent addition to the IBEM-IS. Therefore, data
on age at first newborn screen bloodspot collection was unavailable for most of our subjects.
This is an important limitation to the conclusions of our study, given the findings of others
regarding the relationship of C8 values and age at sample timing for infants with MCADD,
as previously noted (10).
Our findings support the work of others demonstrating significant associations between
higher C8 newborn screen values and homozygosity for the c.985A>G mutation as well as
higher C8 newborn screen values in the presence of other severe ACADM mutations.
Conservative categorization of B genotype alleles may have influenced our results. Some C
genotype alleles may be more deleterious than currently categorized, solely supported by our
literature search, a strategy chosen to minimize the risk that our conclusions overemphasize
the association between deleterious mutations and increasing C8 values.

Author Manuscript

Although this study includes information about a very large number of children with
MCADD, there are important limitations in considering our conclusions. This cohort does
not represent the full denominator of newborn-screened children diagnosed with MCADD in
the catchment area of the participating IBEMC centers. Study limitations include the
potential for selection bias in subject enrollment. We also accepted the premise that all
subjects assigned the condition MCADD in the IBEM-IS are truly affected, and most but not
all subjects in this study had IBEM-IS documentation of at least one biochemical diagnostic
testing abnormality and/or two ACADM allele findings. While the IBEM-IS does not
Mol Genet Metab. Author manuscript; available in PMC 2017 September 01.
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mandate documentation of the rationale for individual diagnostic testing decisions and
practices, we note that of the 10% of subjects with ACADM molecular testing recorded as
“not done” at the time of data extraction, all are minors and all had MCADD biochemical
diagnostic testing performed. Over half of them had at least one biochemical diagnostic
testing abnormality recorded, and the remainder of those subjects had wide ranging (0.50–
28.84 umol/L) first newborn screen C8 values but no MCADD biochemical diagnostic
testing results documented in the IBEM-IS. Finally, though the data collection tools were
designed to primarily elicit fixed responses, rare fields require free-text responses (for
example, genotype) and few fields obligate data entry, yielding the potential for partial or
otherwise inaccurate entry of information. There is also the potential for data entry errors in
the IBEM-IS.
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Additional work by the IBEMC is needed to further clarify and understand the significance
of the 30 additional different ACADM alleles documented in the IBEM-IS for which
published literature referencing the finding was not found. Such work ultimately may or may
not support the genotype allele categorization strategy used in this study, and could
potentially improve understanding of genotype-phenotype correlations. Importantly, this
cohort of newborn-screened subjects allows for the observation of longer-term health
outcomes for individuals with MCADD identified early in life.
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Highlights
•

Retrospective analysis of 221 newborn-screened subjects with MCAD
deficiency (76)

•

NBS C8 and genotype were significant predictors of having neonatal
symptoms (75)

•

Symptomatic neonates were more likely to have at least one copy of
985A>G mutation (82)

•

Neonates with select triggers were more likely to have symptoms (64)

•

The IBEM-IS is a platform to better understand newborn-screened
conditions (74)
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Figure 1.

C8 comparisons by genotype category
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Author Manuscript
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Table 1

Author Manuscript

Characteristics of the 221 study subjects
Characteristic

N
(Total=221)

Percent

<1

100

45%

1–2

55

25%

3–5

39

18%

6–10

24

11%

Missing

3

1.4%

American Indian or Alaska Native

0

0%

Asian

1

0.5%

Black or African American

6

2.7%

Native Hawaiian or Other Pacific Islander

0

0%

White

189

86%

Two or More Races

3

1.4%

Not Reported or Unknown

22

10%

Hispanic or Latino

14

6%

Not Hispanic or Latino

191

86%

Not Reported or Unknown

16

7%

Male

117

53%

Female

104

47%

Done

202

91%

Not done

2

1%

Age (in years) at IBEMC enrollment

Race

Author Manuscript

Ethnicity

Gender

Author Manuscript

Biochemical diagnostic testing for MCADD
Any testing

Plasma acylcarnitine profile
Done

166

75%

Abnormal

161

97%

Within normal limits

4

2%

Urine organic acids
Done

109

49%

Abnormal

82

75%

Within normal limits

20

18%

Author Manuscript

Urine acylglycine profile
Done

16

7%

Abnormal

15

94%

Within normal limits

1

6%

0

0%

Enzyme assay
Done
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Characteristic

Author Manuscript

N
(Total=221)

Percent

5

2%

5

100%

Done

186

84%

Not done

21

10%

Fatty acid oxidation probe assay
Done
Abnormal
Genetic (DNA) testing for MCADD

Author Manuscript
Author Manuscript
Author Manuscript
Mol Genet Metab. Author manuscript; available in PMC 2017 September 01.

Author Manuscript

Mol Genet Metab. Author manuscript; available in PMC 2017 September 01.
fC8 Range

fC8 Median

N

fC8 Range

fC8 Median

N

fC8 Range

fC8 Median

N

fC8 Range

fC8 Median

N

fC8 Range

fC8 Median

N

170

2.50–20.16

9.08

4

1.04–42.30

11.05

11

1.67–26.90

12.45

7

37.96

1

0.72–38.00

3.59

17

0.36–43.91

fC8 Median
fC8 Range

130
8.35

N

27

5.12–14.20

9.66

2

0.50–28.84

7.69

10

12.55

1

6.20–13.88

8.97

3

1.74–30.59

12.45

11

cDone/No Info

2

1.03–3.19

2.11

2

dNot Done

17

1.19–19.35

13.01

8

7.06

1

0.72–26.12

6.64

5

1.04–28.79

5.88

3

eNo Info

221

14

21

9

2

26

149

Total N

IBEM-IS data noted that biochemical diagnostic testing was not done

d

c
IBEM-IS data documented the completion of at least one biochemical diagnostic test, without documentation of actual result findings (normal or abnormal)

IBEM-IS data recorded at least one normal biochemical diagnostic test result, no abnormal biochemical diagnostic test result, with or without unknown/missing biochemical testing information

b

5

3.90

1

2.57

1

0.40–13.40

4.30

3

bNormal

Biochemical Diagnostic Testing for MCADD

IBEM-IS data recorded at least one abnormal biochemical diagnostic test result

a

Total N

DD
Molecular
Unknown

DD
Molecular
Not Done

DD
Molecular
Done

CD

AD

AA, AB, AC, BB, OR CC

aAbnormal

Author Manuscript

Genotype Category & Molecular Testing

Author Manuscript

MCADD diagnostic methods and results

Author Manuscript

Table 2
Bentler et al.
Page 17

Author Manuscript
C8 value (in umol/L) on first newborn screen

IBEM-IS data contained no information on whether biochemical diagnostic testing was done, nor any biochemical diagnostic testing results

Author Manuscript

f

Author Manuscript

e
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Table 3

Author Manuscript

Type and frequency of neonatal triggers, neonatal symptoms, and neonatal abnormal labs
Neonatal Triggers, Symptoms and Abnormal Labs

Frequency of Appearance

aNeonatal Triggers (37 subjects)

Author Manuscript

Poor Feeding

20

Prematurity (<37 weeks gestation)

15

Antibiotics

12

Respiratory distress

7

Infection/sepsis

5

Dehydration

4

Failure to thrive

2

Fever

2

Intralipids

2

Transient Tachypnea of the Newborn

2

Decreased oxygen saturation, fasted, loose stools, mild gastroesophageal reflux, poor growth, poor latch,
vomiting, gavage feeding

1 each

bNeonatal Symptoms (28 subjects)

Author Manuscript

Lethargy

13

Distress

9

Tachypnea

8

Hypoglycemia

5

Hypothermia

3

Hypotonia

3

Irritability

3

Cardiomyopathy

2

Sleepy

2

Apnea, hepatomegaly, limp, metabolic acidosis, Echo: mild left hypertrophy, pallor, seizure, sweaty,
tachycardia, temperature instability

1 each

cNeonatal Abnormal Labs (21 subjects)
Hypoglycemia

20

Elevated liver function tests

7

Metabolic acidosis

6

Elevated uric acid

3

Low Co2

2

Hyperuricemia

2

Elevated C reactive protein, abnormal carnitine level, abnormal CMP, elevated BUN, elevated CK, elevated
creatinine, hyperammonemia, ketonuria, slight elevation ALT

1 each

Author Manuscript

a

neonatal complications and interventions suggestive of underlying health complications in the data determined by clinician authors as most likely
to result in potential MCADD symptoms.

b

neonatal symptoms in the data determined by clinician authors as consistent with MCADD, many based on reports of symptoms manifested in
individuals affected with MCADD. IBEM-IS data entry does not require clinician specification of whether a subject’s symptoms were ultimately
attributed to or related to the particular IBEM diagnosis.
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c

neonatal laboratory test abnormalities in the data determined by clinician authors to be of potential concern in the context of MCADD (excluding
newborn screening and MCADD diagnostic biochemical and molecular test results).

Author Manuscript
Author Manuscript
Author Manuscript
Author Manuscript
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Table 4

Author Manuscript

Comparison of the first newborn screen C8 value by select characteristics
Factor

Mean C8

Median C8

Std. Dev. From Mean

Mean Rank

Female (n=104)

10.15

8.32

8.25

109.61

Male (n=117)

12.13

8.69

11.48

112.24

Yes (n=97)

12.16

10.28

10.24

89.66

No (n=76)

10.96

8.24

10.36

83.61

Yes (n=13)

7.51

2.85

10.54

73

No (n=200)

11.58

8.93

10.07

109.21

Yes (n=37)

13.24

11.7

11.80

106.84

No (n=161)

11.00

8.6

9.77

97.81

Yes (n=28)

16.32

13.35

11.99

114.36

No (n=152)

10.48

8.37

9.62

86.11

Yes (n=21)

18.46

14.93

12.42

59.45

No (n=68)

10.12

8.32

9.45

40.54

AA (n=69)

15.76

13.36

10.76

96.00

AB (n=18)

11.89

11.00

10.24

80.72

AC (n=49)

5.73

3.65

6.51

49.24

CC (n=12)

4.63

3.37

4.31

44.67

AA&AB (n=87)

14.96

13.30

10.71

92.84

AC&CC (n=61)

6.83

3.72

6.13

48.34

Gender

Breastfed Only

Low Birthweight

Neonatal Triggers

Author Manuscript

Neonatal Symptoms

Neonatal Abnormal Labs

Genotype (Four Categories)

Author Manuscript

Genotype (Two Categories)

Author Manuscript
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Table 5

Author Manuscript

aDifferent

ACADM allele findings of the 221 study subjects

Allele

Author Manuscript
Author Manuscript
a

Genotype Category Assigned

Reference

bc.985A>G (p.K329E or p.K304E)

A

(21) (22)

c.233T>C

B

(23) (24)

c.1102_1105delTTAG

B

(25) (26)

c.734C>T(p.S245L)

B

(23) (25)

c.1238G>A (p.R413H)

B

(25)

c.928G>A

B

(23)

c.362 C>T

B

(23) (27)

c.347G>A

B

(28)

cc.799G>A

B

(29)

N=2 additional different deletions, not found by published literature search, were recorded in
the IBEM-IS

B

c.127 G>A (p.E43K)

C

(25)

c.797A>G

C

(25)

c.1207A>G

C

(25)

c.600-18G>A

C

(25) (31)

c.554T>C

C

(25)

c.443G>A

C

(25)

c.757G>A

C

(25)

c.1115C>A (p.A372D)

C

(25)

c.526G>A

C

(25)

c.(−34)T>C

C

(25)

c.558T>A

C

(4)

dc.199T>C (Y67H; Y42H)

C

(23)

c.387+1delG

C

(30)

c.157C>T

C

(32)

c.583G>A

C

(33)

c.728G>A

C

(4)

c.617G>T (p.R206L)

C

(30)

c.447 G>A

C

(29) (34)

c.250C>T (p.L84F)

C

(25)

c.92G>A

C

(35)

N=28 additional different allele findings, not found by published literature search, were
recorded in the IBEM-IS

C

Excludes subjects with empty and indecipherable entries in the allele data fields (genotype category D)

Author Manuscript

b

Frequency of genotype category A allele is 231

c

Most frequently appearing genotype category B allele (n=6)

d

Most frequently appearing genotype category C allele (n=14).
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